Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis

Kodama,Junichi; Sasaki,Aiko; Masahiro,Satoko; Seki,Noriko; Kusumoto,Tomoyuki; Nakamura,Keiichiro; Hongo,Atsushi; Hiramatsu,Yuji

doi:10.3892/ol_00000090

May-June 2010 Volume 1 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-June 2010 Volume 1 Issue 3

Full Size Image

Article

Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis

Authors:
- Junichi Kodama
- Aiko Sasaki
- Satoko Masahiro
- Noriko Seki
- Tomoyuki Kusumoto
- Keiichiro Nakamura
- Atsushi Hongo
- Yuji Hiramatsu
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. kodama@cc.okayama-u.ac.jp
Pages: 511-513
|
Published online on: May 1, 2010

https://doi.org/10.3892/ol_00000090
Expand metrics +

Abstract

Few reports delineate the pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in hemodialysis (HD) patients with epithelial ovarian cancer. However, the optimal carboplatin dose and the timing of HD have yet to be elucidated. We presented a case of an advanced-stage epithelial ovarian cancer patient with chronic renal failure requiring HD. After 4 courses of combination chemotherapy consisting of paclitaxel and carboplatin, a partial response was obtained; therefore, she underwent interval debulking surgery. Paclitaxel was administered for 3 h at a dose of 150 mg/m2, and carboplatin was administered for 1 h at a dose of 4-7 area under the concentration/time curve (AUC), which was calculated by the Calvert formula. HD was initiated 24 h after the start of administration of carboplatin and performed for a period of 3 h. Pharmacokinetic studies showed that the AUCs of free platinum and paclitaxel were 3.48-5.55 mg·min/ml and 13.5 µg·h/ml, respectively. Combination chemotherapy consisting of paclitaxel and carboplatin is a feasible approach to improving the treatment outcome of epithelial ovarian cancer patients with chronic renal failure requiring HD. The measurement of free platinum is useful in determining the optimal dose of carboplatin in order to obtain an adequate AUC. Determining the dose of carboplatin according to the Calvert formula and initiating HD after 24 h would ensure a favorable therapeutic effect with limited side effects.

View Figures

View References

1	Berek JS and Natarajan S: Ovarian and fallopian cancer. Berek & Novak’s Gynecology. 14th edition. Berek JS: Lippincott Williams & Wilkins; pp. 1457–1647. 2007
2	Hollet JL: Screening, diagnosis and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol. 2:604–610. 2007. View Article : Google Scholar : PubMed/NCBI
3	Chatelut E, Rostaing L, Gualano V, et al: Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron. 66:157–161. 1994. View Article : Google Scholar : PubMed/NCBI
4	Watanabe M, Aoki Y, Tomita M, et al: Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol. 84:335–338. 2002. View Article : Google Scholar : PubMed/NCBI
5	Yokoyama Y, Futagami M, Higuchi T, et al: Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis – case report. Eur J Gynaecol Oncol. 27:437–439. 2006.PubMed/NCBI
6	Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 11:1748–1756. 1989.PubMed/NCBI
7	LeRoy AF, Wehling ML, Sponseller HL, et al: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 18:184–191. 1977. View Article : Google Scholar : PubMed/NCBI
8	Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep. 71:53–59. 1987.PubMed/NCBI
9	Sonnichsen DS and Relling MV: Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet. 27:256–269. 1994. View Article : Google Scholar : PubMed/NCBI
10	Motzer RJ, Niedzwiecki D, Isaacs M, et al: Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol. 27:234–238. 1990. View Article : Google Scholar : PubMed/NCBI
11	Yanagawa H, Takishita Y, Bando H, et al: Carboplatin-based chemotherapy in patients undergoing hemodialysis. Anticancer Res. 16:533–536. 1996.PubMed/NCBI
12	Inoue A, Saijo Y, Kikuchi T, et al: Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol. 15:51–54. 2004. View Article : Google Scholar : PubMed/NCBI
13	Takezawa K, Okamoto I, Fukuoka M, et al: Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J Thorac Oncol. 3:1073–1075. 2008. View Article : Google Scholar : PubMed/NCBI
14	Jeyabalan N, Hirte HW and Moens F: Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. Int J Gynecol Cancer. 10:463–468. 2000. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles